Sectoral Asset Management
Latest statistics and disclosures from Sectoral Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LENZ, LLY, BOLD, UNH, MRK, and represent 31.02% of Sectoral Asset Management's stock portfolio.
- Added to shares of these 10 stocks: LENZ (+$24M), BOLD (+$12M), ZBH, REGN, PGNY, CNC, NARI, CYTK, ISRG, SYK.
- Started 14 new stock positions in SRRK, ZBH, PGNY, SYK, COGT, ATEC, ELV, EFTR, ISRG, KYTX. BOLD, CNC, LENZ, NARI.
- Reduced shares in these 10 stocks: EWTX, AMGN, VERA, ANNX, FDMT, STRO, REPL, TVTX, PMVP, PRVA.
- Sold out of its positions in ACAD, ALLK, AMLX, ANNX, AXNX, BCAB, CNMD, EWTX, Effector Therapeutics, FDMT.
- Sectoral Asset Management was a net buyer of stock by $5.6M.
- Sectoral Asset Management has $254M in assets under management (AUM), dropping by 9.54%.
- Central Index Key (CIK): 0001274413
Tip: Access up to 7 years of quarterly data
Positions held by Sectoral Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Sectoral Asset Management
Sectoral Asset Management holds 92 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Lenz Therapeutics (LENZ) | 9.4 | $24M | NEW | 1.1M | 22.33 |
|
| Eli Lilly & Co. (LLY) | 7.8 | $20M | -3% | 26k | 777.96 |
|
| Boundless Bio (BOLD) | 4.8 | $12M | NEW | 856k | 14.25 |
|
| UnitedHealth (UNH) | 4.5 | $12M | +22% | 23k | 494.70 |
|
| Merck & Co (MRK) | 4.5 | $11M | +8% | 87k | 131.95 |
|
| Abbott Laboratories (ABT) | 3.1 | $8.0M | 70k | 113.66 |
|
|
| Johnson & Johnson (JNJ) | 3.0 | $7.6M | -11% | 48k | 158.19 |
|
| Mineralys Therapeutics (MLYS) | 2.8 | $7.1M | -8% | 552k | 12.91 |
|
| Regeneron Pharmaceuticals (REGN) | 2.7 | $6.8M | +84% | 7.1k | 962.49 |
|
| Abbvie (ABBV) | 2.5 | $6.4M | -23% | 35k | 182.10 |
|
| Boston Scientific Corporation (BSX) | 2.3 | $5.9M | -5% | 87k | 68.49 |
|
| Thermo Fisher Scientific (TMO) | 2.3 | $5.8M | +11% | 10k | 581.21 |
|
| Pfizer (PFE) | 2.1 | $5.3M | 189k | 27.75 |
|
|
| Amgen (AMGN) | 1.8 | $4.6M | -43% | 16k | 284.32 |
|
| BioMarin Pharmaceutical (BMRN) | 1.8 | $4.5M | +3% | 52k | 87.34 |
|
| Dex (DXCM) | 1.8 | $4.5M | +10% | 32k | 138.70 |
|
| Danaher Corporation (DHR) | 1.7 | $4.4M | +18% | 18k | 249.72 |
|
| Zimmer Holdings (ZBH) | 1.5 | $3.9M | NEW | 30k | 131.98 |
|
| Argenx Se Spn Adr (ARGX) | 1.4 | $3.7M | -7% | 9.3k | 393.72 |
|
| Iqvia Holdings (IQV) | 1.4 | $3.6M | -15% | 14k | 252.89 |
|
| Medtronic SHS (MDT) | 1.3 | $3.3M | -4% | 38k | 87.15 |
|
| Insulet Corporation (PODD) | 1.2 | $3.1M | +39% | 18k | 171.40 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.2 | $3.0M | -21% | 7.2k | 418.01 |
|
| Cytokinetics (CYTK) | 1.2 | $3.0M | +507% | 43k | 70.11 |
|
| Progyny (PGNY) | 1.1 | $2.9M | NEW | 76k | 38.15 |
|
| Gilead Sciences (GILD) | 1.1 | $2.8M | -5% | 39k | 73.25 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.1 | $2.8M | -18% | 19k | 149.45 |
|
| Icon SHS (ICLR) | 1.0 | $2.7M | -22% | 7.9k | 335.95 |
|
| Centene Corporation (CNC) | 1.0 | $2.7M | NEW | 34k | 78.48 |
|
| Amicus Therapeutics (FOLD) | 1.0 | $2.6M | +40% | 221k | 11.78 |
|
| Inari Medical Ord (NARI) | 1.0 | $2.5M | NEW | 53k | 47.98 |
|
| Intuitive Surgical (ISRG) | 1.0 | $2.4M | NEW | 6.1k | 399.09 |
|
| Stryker Corporation (SYK) | 0.9 | $2.4M | NEW | 6.6k | 357.87 |
|
| Moonlake Immunothera Class A (MLTX) | 0.9 | $2.3M | +54% | 46k | 50.23 |
|
| Goodrx Hldgs (GDRX) | 0.9 | $2.3M | -11% | 321k | 7.10 |
|
| Sarepta Therapeutics (SRPT) | 0.9 | $2.2M | -19% | 17k | 129.46 |
|
| Option Care Health (OPCH) | 0.8 | $2.1M | 64k | 33.54 |
|
|
| Silverback Therapeutics (SPRY) | 0.8 | $2.1M | -42% | 204k | 10.22 |
|
| Arvinas Ord (ARVN) | 0.8 | $2.0M | -26% | 49k | 41.28 |
|
| Vera Therapeutics Cl A (VERA) | 0.8 | $1.9M | -63% | 45k | 43.12 |
|
| Eyepoint Pharmaceuticals (EYPT) | 0.8 | $1.9M | +13% | 92k | 20.67 |
|
| Alphatec Holdings In Com New (ATEC) | 0.7 | $1.9M | NEW | 136k | 13.79 |
|
| Iteos Therapeutics (ITOS) | 0.7 | $1.8M | -39% | 134k | 13.64 |
|
| Anthem (ELV) | 0.7 | $1.8M | NEW | 3.5k | 518.54 |
|
| Cogent Biosciences (COGT) | 0.7 | $1.8M | NEW | 264k | 6.72 |
|
| Arcus Biosciences Incorporated (RCUS) | 0.7 | $1.8M | -3% | 94k | 18.88 |
|
| Astrazeneca Spn Adr (AZN) | 0.7 | $1.7M | -6% | 24k | 67.75 |
|
| Humana (HUM) | 0.6 | $1.6M | -42% | 4.8k | 346.72 |
|
| Acelyrin (SLRN) | 0.6 | $1.6M | -25% | 244k | 6.75 |
|
| Olema Pharmaceuticals (OLMA) | 0.6 | $1.6M | +627% | 140k | 11.32 |
|
| Moderna (MRNA) | 0.6 | $1.6M | -8% | 15k | 106.56 |
|
| Biogen Idec (BIIB) | 0.6 | $1.5M | -55% | 7.0k | 215.63 |
|
| Edwards Lifesciences (EW) | 0.6 | $1.5M | -28% | 16k | 95.56 |
|
| Effector Therapeutics (EFTR) | 0.5 | $1.4M | NEW | 95k | 14.39 |
|
| Turnstone Biologics Corp (TSBX) | 0.5 | $1.4M | 518k | 2.62 |
|
|
| Summit Therapeutics (SMMT) | 0.5 | $1.3M | +950% | 315k | 4.14 |
|
| Altimmune (ALT) | 0.4 | $939k | -45% | 92k | 10.18 |
|
| Verastem (VSTM) | 0.3 | $876k | -63% | 74k | 11.80 |
|
| Illumina (ILMN) | 0.3 | $862k | -4% | 6.3k | 137.32 |
|
| Sanofi Spn Adr (SNY) | 0.2 | $616k | -10% | 13k | 48.60 |
|
| Ascendis Pharma A S Spn Adr (ASND) | 0.2 | $606k | -9% | 4.0k | 151.17 |
|
| United Therapeutics Corporation (UTHR) | 0.2 | $596k | -7% | 2.6k | 229.72 |
|
| Royalty Pharma Shs Cl A (RPRX) | 0.2 | $590k | -5% | 19k | 30.37 |
|
| Vaxcyte (PCVX) | 0.2 | $581k | +5% | 8.5k | 68.31 |
|
| Neurocrine Biosciences (NBIX) | 0.2 | $579k | -5% | 4.2k | 137.92 |
|
| Beigene Spn Adr (BGNE) | 0.2 | $577k | 3.7k | 156.39 |
|
|
| Apellis Pharmaceuticals (APLS) | 0.2 | $568k | +85% | 9.7k | 58.78 |
|
| Incyte Corporation (INCY) | 0.2 | $536k | -6% | 9.4k | 56.97 |
|
| Medpace Hldgs (MEDP) | 0.2 | $522k | -5% | 1.3k | 404.15 |
|
| Roivant Sciences SHS (ROIV) | 0.2 | $521k | +35% | 50k | 10.54 |
|
| Bridgebio Pharma (BBIO) | 0.2 | $498k | +24% | 16k | 30.92 |
|
| Intra Cellular Therapies (ITCI) | 0.2 | $490k | -4% | 7.1k | 69.20 |
|
| Jazz Pharma Shs Usd (JAZZ) | 0.2 | $469k | -4% | 3.9k | 120.42 |
|
| Insmed (INSM) | 0.2 | $446k | +18% | 16k | 27.13 |
|
| Ionis Pharmaceuticals (IONS) | 0.2 | $438k | +55% | 10k | 43.35 |
|
| Blueprint Medicines (BPMC) | 0.2 | $418k | +78% | 4.4k | 94.86 |
|
| Revolution Medicines (RVMD) | 0.2 | $416k | -5% | 13k | 32.23 |
|
| Dr Reddys Labs Adr (RDY) | 0.2 | $403k | +22% | 5.5k | 73.35 |
|
| Rocket Pharmaceuticals (RCKT) | 0.2 | $399k | +20% | 15k | 26.94 |
|
| Alkermes SHS (ALKS) | 0.2 | $385k | -7% | 14k | 27.07 |
|
| Biontech Se Spn Adr (BNTX) | 0.1 | $325k | -5% | 3.5k | 92.25 |
|
| Exelixis (EXEL) | 0.1 | $312k | -6% | 13k | 23.73 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.1 | $302k | -5% | 1.1k | 267.04 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.1 | $274k | NEW | 15k | 17.76 |
|
| Structure Therapeu Spn Adr (GPCR) | 0.1 | $256k | +75% | 6.0k | 42.86 |
|
| Denali Therapeutics (DNLI) | 0.1 | $248k | -6% | 12k | 20.52 |
|
| Intellia Therapeutics (NTLA) | 0.1 | $242k | -5% | 8.8k | 27.51 |
|
| Halozyme Therapeutics (HALO) | 0.1 | $231k | -5% | 5.7k | 40.68 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.1 | $220k | -6% | 7.7k | 28.60 |
|
| Kyverna Therapeutics (KYTX) | 0.1 | $174k | NEW | 7.0k | 24.84 |
|
| Legend Biotech Corp Spn Adr (LEGN) | 0.1 | $168k | 3.0k | 56.09 |
|
|
| Zai Lab Adr (ZLAB) | 0.0 | $32k | -50% | 2.0k | 16.02 |
|
Past Filings by Sectoral Asset Management
SEC 13F filings are viewable for Sectoral Asset Management going back to 2010
- Sectoral Asset Management 2024 Q1 filed May 14, 2024
- Sectoral Asset Management 2023 Q4 filed Feb. 14, 2024
- Sectoral Asset Management 2023 Q3 filed Nov. 14, 2023
- Sectoral Asset Management 2023 Q2 filed Aug. 11, 2023
- Sectoral Asset Management 2023 Q1 filed May 12, 2023
- Sectoral Asset Management 2022 Q4 filed Feb. 10, 2023
- Sectoral Asset Management 2022 Q3 filed Nov. 10, 2022
- Sectoral Asset Management 2022 Q2 filed Aug. 15, 2022
- Sectoral Asset Management 2022 Q1 filed May 10, 2022
- Sectoral Asset Management 2021 Q4 filed Feb. 11, 2022
- Sectoral Asset Management 2021 Q3 filed Nov. 15, 2021
- Sectoral Asset Management 2021 Q2 filed Aug. 16, 2021
- Sectoral Asset Management 2021 Q1 filed May 14, 2021
- Sectoral Asset Management 2020 Q4 filed Feb. 12, 2021
- Sectoral Asset Management 2020 Q3 filed Nov. 13, 2020
- Sectoral Asset Management 2020 Q2 filed Aug. 13, 2020